-
1.
公开(公告)号:EP2348857B1
公开(公告)日:2016-02-24
申请号:EP09822430.6
申请日:2009-10-12
发明人: BOOKSER, Brett, C. , DANG, Qun , GIBSON, Tony, S. , JIANG, Hongjian , CHUNG, De Michael , BAO, Jianming , JIANG, Jinlong , KASSICK, Andy , KEKEC, Ahmet , LAN, Ping , LU, Huagang , MAKARA, Gergely, M. , ROMERO, F., Anthony , SEBHAT, Iyassu , WILSON, David , WODKA, Dariusz
IPC分类号: C07F9/6506 , C07F9/6558 , C07F9/6571 , A61K31/415
CPC分类号: C07F9/65068 , C07F9/65583 , C07F9/657181
-
2.
公开(公告)号:EP2348857A1
公开(公告)日:2011-08-03
申请号:EP09822430.6
申请日:2009-10-12
发明人: BOOKSER, Brett, C. , DANG, Qun , GIBSON, Tony, S. , JIANG, Hongjian , CHUNG, De Michael , BAO, Jianming , JIANG, Jinlong , KASSICK, Andy , KEKEC, Ahmet , LAN, Ping , LU, Huagang , MAKARA, Gergely, M. , ROMERO, F., Anthony , SEBHAT, Iyassu , WILSON, David , WODKA, Dariusz
IPC分类号: A01N43/50 , A61K31/415 , C07D243/08
CPC分类号: C07F9/65068 , C07F9/65583 , C07F9/657181
摘要: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, Metabolic Syndrome, obesity, hypercholesterolemia, and hypertension.
-
公开(公告)号:EP3924343A1
公开(公告)日:2021-12-22
申请号:EP09792782.6
申请日:2009-09-21
发明人: BOOKSER, Brett, C. , DANG, Qun , GIBSON, Tony, S. , JIANG, Hongjian , CHUNG, De Michael , BAO, Jianming , JIANG, Jinlong , KASSICK, Andy , KEKEC, Ahmet , LAN, Ping , LU, Huagang , MAKARA, Gergely, M. , ROMERO, F. Anthony , SEBHAT, Iyassu , WILSON, David , WODKA, Dariusz
IPC分类号: C07D235/26 , C07D235/28 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , A61K31/4184 , A61K31/4439 , A61P3/10
-
公开(公告)号:EP2888007A1
公开(公告)日:2015-07-01
申请号:EP13830944.8
申请日:2013-08-15
发明人: APGAR, James, M. , BIFTU, Tesfaye , CHEN, Ping , FENG, Danqing , HICKS, Jacqueline, D. , KEKEC, Ahmet , LEAVITT, Kenneth, J. , LI, Bing , SEBHAT, Iyassu , QIAN, Xiaoxia , WEI, Lan , WILKENING, Robert, R. , WU, Zhicai
IPC分类号: A61P3/10 , A61K31/4184 , A61K31/415 , A61K31/454
CPC分类号: C07D417/14 , A61K31/366 , A61K31/397 , A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/427 , A61K31/4985 , A61K31/506 , A61K31/5377 , C07D405/12 , C07D405/14 , C07D413/14
摘要: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
摘要翻译: 结构式(I)的新型化合物是AMP-蛋白激酶的激活剂,并且可用于治疗,预防和抑制由AMPK-活化的蛋白激酶介导的疾病。 本发明的化合物可用于治疗2型糖尿病,高血糖症,代谢综合征,肥胖症,高胆固醇血症和高血压。
-
公开(公告)号:EP4003405A1
公开(公告)日:2022-06-01
申请号:EP20848160.6
申请日:2020-07-23
-
公开(公告)号:EP3773683A1
公开(公告)日:2021-02-17
申请号:EP19784326.1
申请日:2019-04-08
-
公开(公告)号:EP3768291A1
公开(公告)日:2021-01-27
申请号:EP19772613.6
申请日:2019-03-18
发明人: KEKEC, Ahmet , KEVIN, Nancy Jo , LI, Bing , LIN, Songnian , PARISH, Craig A. , TANG, Weijuan
-
公开(公告)号:EP3740212A2
公开(公告)日:2020-11-25
申请号:EP18890684.6
申请日:2018-12-13
-
公开(公告)号:EP3463413A1
公开(公告)日:2019-04-10
申请号:EP17803382.5
申请日:2017-05-23
-
公开(公告)号:EP2888008B1
公开(公告)日:2018-12-26
申请号:EP13831336.6
申请日:2013-08-19
发明人: APGAR, James, M. , BIFTU, Tesfaye , CHEN, Ping , FENG, Danqing , HICKS, Jacqueline, D. , KEKEC, Ahmet , LEAVITT, Kenneth, J. , LI, Bing , SEBHAT, Iyassu , QIAN, Xiaoxia , WEI, Lan , WILKENING, Robert, R. , WU, Zhicai , ARASAPPAN, Ashok
IPC分类号: C07D471/04 , C07D519/00 , A61P3/10 , A61K31/4184 , A61K31/415 , A61K31/454
CPC分类号: C07D471/04 , A61K31/19 , A61K31/366 , A61K31/397 , A61K31/437 , A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/5377 , C07C53/18 , C07D519/00 , A61K2300/00
摘要: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
-
-
-
-
-
-
-
-
-